Dual Antiangiogenesis Agents Bevacizumab Plus Trebananib, without Chemotherapy, in First-line Treatment of Metastatic Colorectal Cancer: Results of a Phase II Study
Jennifer Mooi, Fiona Chionh, Peter Savas, Jessica Da Gama Duarte, Geoffrey Chong, Stephen Brown, Rachel Wong, Timothy J Price, Alysson Wann, Effie Skrinos, John M Mariadason, Niall C Tebbutt
CLINICAL CANCER RESEARCH | AMER ASSOC CANCER RESEARCH | Published : 2021
PURPOSE: To assess the efficacy and safety of dual antiangiogenesis agents, bevacizumab plus trebananib, without chemotherapy, in first-line treatment of metastatic colorectal cancer (mCRC). PATIENTS AND METHODS: This open-label phase II study enrolled patients with unresectable mCRC with no prior systemic treatment. All patients received bevacizumab 7.5 mg/kg 3-weekly and trebananib 15 mg/kg weekly. The primary endpoint was disease control [stable disease, partial response (PR), or complete response (CR)] at 6 months (DC6m). Secondary endpoints included toxicity, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). Exploratory biomarkers in plasma angioge..View full abstract
Awarded by NHMRC Senior Research Fellowships
We thank Amgen for supplying the study treatments. J. Da Gama Duarte was funded by Cure Cancer Australia through the Cancer Australia Priority-Driven Cancer Research Scheme. J.M. Mariadason was funded by NHMRC Senior Research Fellowships (1046092). The Olivia Newton-John Cancer Research Institute acknowledges the support of the Operational Infrastructure Support Program, Victorian Government, Australia.